Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are pleased to announce that Professor Lê Văn Tấn has been appointed Interim Director of OUCRU Ho Chi Minh City, with effect from 24 June.

Le Van Tan

Professor Lê Văn Tấn joined OUCRU in 2003, and over the past two decades has grown into one of Viet Nam’s leading scientists in emerging infectious diseases. In 2025, he was appointed Full Professor at the University of Oxford.

His work has centered on helping Viet Nam prepare for and respond to emerging infectious threats, from avian influenza, hand, foot and mouth disease, and COVID-19, to measles and mpox. In close partnership with the Hospital for Tropical Diseases (HTD), Children’s Hospital 1, Institute of Pasteur in Nha Trang, National Institute of Hygiene and Epidemiology (NIHE), Ho Chi Minh City Department of Health, Ho Chi Minh City Centre for Disease Control (HCDC), and other local partners, his team has strengthened rapid testing, genomic surveillance, serum banking, and outbreak response systems to provide timely evidence for public health decision-making.

Under his leadership, the reach of OUCRU’s work has extended well beyond Viet Nam. One of international Consortia he is currently leading is the SEACOVARIANTS, a Wellcome-funded regional initiative building capacity for surveillance and epidemic preparedness. SEACOVARIANTS was instrumental in OUCRU and the Hospital for Tropical Diseases being designated a WHO CoViNet reference laboratory for coronavirus surveillance in 2026.

Professor Tấn’s appointment recognises his scientific leadership, his long-standing partnerships in Viet Nam, and his commitment to training the next generation of Vietnamese researchers.

Professor Kevin Baird remains Interim Programme Director of OUCRU, overseeing its four units in Viet Nam, Indonesia and Nepal.

The full story is available on the OUCRU website.

Similar stories

Building the world's evidence base to tackle drug-resistant tuberculosis

£10 million international research programme launches across India, Kazakhstan, Mozambique, South Africa and Vietnam.

A New Layer of Control for a Decades-Old Leukemia Drug

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led jointly by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

MORU’s contribution to ASEAN health highlighted during The Princess Royal’s Thailand visit

The visit highlighted MORU’s longstanding contribution to health across Thailand and the wider ASEAN region, and the value of collaboration between Mahidol University and Oxford's Nuffield Department of Medicine.

Patient enrolment begins in PARTNERS trial to identify the first effective treatments for Bundibugyo virus disease

Patient enrolment has begun in the Democratic Republic of the Congo for the PARTNERS clinical trial of treatments for Bundibugyo virus disease (BVD). The trial is led in the DRC by the Institute National pour la Recherche Biomedicale, supported by the Institute of Tropical Medicine in Belgium, Ministry of Public Health of the Democratic Republic of the Congo, ALIMA (The Alliance for International Medical Action) and outbreak response teams from Médecins Sans Frontières (MSF). International trial coordination is led by the Pandemic Sciences Institute at the University of Oxford.

Decades old puzzle solved as scientists uncover cause of inflammatory bowel disease

Scientists have identified the missing link between a long-known genetic signal in inflammatory bowel disease and a damaging immune response that switches off the body’s natural control of inflammation - opening the door to faster diagnosis and targeted treatment.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.